Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies

Complexity of tumor vasculature in clear cell renal cell carcinoma

(2010) Chao-Nan Qian et al.   CANCER

Immunotherapy of distant metastatic disease

(2009) D. Schadendorf et al.   ANNALS OF ONCOLOGY

poster presentation urological cancers

(2009)   ANNALS OF ONCOLOGY

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases

(2009) Harprit Singh et al.   CELLULAR SIGNALLING

Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma

(2009) I. Helfrich et al.   CLINICAL CANCER RESEARCH

Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib

(2009) L. Jilaveanu et al.   CLINICAL CANCER RESEARCH

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

(2009) Ronald B. Natale et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

(2009) Axel Hauschild et al.   JOURNAL OF CLINICAL ONCOLOGY

Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon

(2009) Marna G. Bouwhuis et al.   JNCI-Journal of the National Cancer Institute

Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma

(2009) Lavanya H Palavalli et al.   NATURE GENETICS

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma

(2008) Domingo G. Perez et al.   CANCER

Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells

(2008) F. Shojaei et al.   CANCER RESEARCH

Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group

(2008) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?

(2008) Vernon K Sondak et al.   LANCET

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

(2008) Alexander MM Eggermont et al.   LANCET

Preliminary Results of the Combination of Bevacizumab and Weekly Paclitaxel in Advanced Melanoma

(2008) M. González-Cao et al.   ONCOLOGY

Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead

(2007) V. W.M. van Hinsbergh et al.   CARDIOVASCULAR RESEARCH